The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Peptide Cancer Vaccine Market Research Report 2024
Synopsis
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
The global Peptide Cancer Vaccine market was valued at US$ 546.9 million in 2023 and is anticipated to reach US$ 1964.1 million by 2030, witnessing a CAGR of 19.8% during the forecast period 2024-2030.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.
Report Scope
The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Pipeline, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Pipeline, by Application, and by regions.
Market Segmentation
By Company
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Segment by Application
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Pipeline, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Peptide Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
The global Peptide Cancer Vaccine market was valued at US$ 546.9 million in 2023 and is anticipated to reach US$ 1964.1 million by 2030, witnessing a CAGR of 19.8% during the forecast period 2024-2030.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.
Report Scope
The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Pipeline, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Pipeline, by Application, and by regions.
Market Segmentation
By Company
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Segment by Application
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Pipeline, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Peptide Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Peptide Cancer Vaccine Market Overview
1.1 Product Overview and Scope of Peptide Cancer Vaccine
1.2 Peptide Cancer Vaccine Segment by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Value Comparison by Pipeline (2024-2030)
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Peptide Cancer Vaccine Segment by Application
1.3.1 Global Peptide Cancer Vaccine Market Value by Application: (2024-2030)
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts
1.4.1 Global Peptide Cancer Vaccine Revenue 2019-2030
1.4.2 Global Peptide Cancer Vaccine Sales 2019-2030
1.4.3 Global Peptide Cancer Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Peptide Cancer Vaccine Market Competition by Manufacturers
2.1 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Peptide Cancer Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Peptide Cancer Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Peptide Cancer Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Peptide Cancer Vaccine, Product Type & Application
2.7 Peptide Cancer Vaccine Market Competitive Situation and Trends
2.7.1 Peptide Cancer Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Peptide Cancer Vaccine Players Market Share by Revenue
2.7.3 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Peptide Cancer Vaccine Retrospective Market Scenario by Region
3.1 Global Peptide Cancer Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Peptide Cancer Vaccine Global Peptide Cancer Vaccine Sales by Region: 2019-2030
3.2.1 Global Peptide Cancer Vaccine Sales by Region: 2019-2024
3.2.2 Global Peptide Cancer Vaccine Sales by Region: 2025-2030
3.3 Global Peptide Cancer Vaccine Global Peptide Cancer Vaccine Revenue by Region: 2019-2030
3.3.1 Global Peptide Cancer Vaccine Revenue by Region: 2019-2024
3.3.2 Global Peptide Cancer Vaccine Revenue by Region: 2025-2030
3.4 North America Peptide Cancer Vaccine Market Facts & Figures by Country
3.4.1 North America Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Peptide Cancer Vaccine Sales by Country (2019-2030)
3.4.3 North America Peptide Cancer Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Peptide Cancer Vaccine Market Facts & Figures by Country
3.5.1 Europe Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2030)
3.5.3 Europe Peptide Cancer Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Peptide Cancer Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Peptide Cancer Vaccine Market Facts & Figures by Country
3.7.1 Latin America Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Peptide Cancer Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Peptide Cancer Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Pipeline
4.1 Global Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
4.1.1 Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024)
4.1.2 Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030)
4.1.3 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2030)
4.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
4.2.1 Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2025-2030)
4.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2030)
4.3 Global Peptide Cancer Vaccine Price by Pipeline (2019-2030)
5 Segment by Application
5.1 Global Peptide Cancer Vaccine Sales by Application (2019-2030)
5.1.1 Global Peptide Cancer Vaccine Sales by Application (2019-2024)
5.1.2 Global Peptide Cancer Vaccine Sales by Application (2025-2030)
5.1.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030)
5.2.1 Global Peptide Cancer Vaccine Revenue by Application (2019-2024)
5.2.2 Global Peptide Cancer Vaccine Revenue by Application (2025-2030)
5.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Peptide Cancer Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Boston Biomedical
6.1.1 Boston Biomedical Corporation Information
6.1.2 Boston Biomedical Description and Business Overview
6.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
6.1.5 Boston Biomedical Recent Developments/Updates
6.2 Ultimovacs
6.2.1 Ultimovacs Corporation Information
6.2.2 Ultimovacs Description and Business Overview
6.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
6.2.5 Ultimovacs Recent Developments/Updates
6.3 BrightPath Biotherapeutics
6.3.1 BrightPath Biotherapeutics Corporation Information
6.3.2 BrightPath Biotherapeutics Description and Business Overview
6.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
6.3.5 BrightPath Biotherapeutics Recent Developments/Updates
6.4 TapImmune
6.4.1 TapImmune Corporation Information
6.4.2 TapImmune Description and Business Overview
6.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
6.4.5 TapImmune Recent Developments/Updates
6.5 Immatics
6.5.1 Immatics Corporation Information
6.5.2 Immatics Description and Business Overview
6.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
6.5.5 Immatics Recent Developments/Updates
6.6 Sellas
6.6.1 Sellas Corporation Information
6.6.2 Sellas Description and Business Overview
6.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
6.6.5 Sellas Recent Developments/Updates
6.7 Imugene
6.6.1 Imugene Corporation Information
6.6.2 Imugene Description and Business Overview
6.6.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Imugene Peptide Cancer Vaccine Product Portfolio
6.7.5 Imugene Recent Developments/Updates
6.8 VAXON Biotech
6.8.1 VAXON Biotech Corporation Information
6.8.2 VAXON Biotech Description and Business Overview
6.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
6.8.5 VAXON Biotech Recent Developments/Updates
6.9 Generex Biotechnology
6.9.1 Generex Biotechnology Corporation Information
6.9.2 Generex Biotechnology Description and Business Overview
6.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
6.9.5 Generex Biotechnology Recent Developments/Updates
6.10 ISA Pharmaceuticals
6.10.1 ISA Pharmaceuticals Corporation Information
6.10.2 ISA Pharmaceuticals Description and Business Overview
6.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
6.10.5 ISA Pharmaceuticals Recent Developments/Updates
6.11 OncoTherapy Science
6.11.1 OncoTherapy Science Corporation Information
6.11.2 OncoTherapy Science Peptide Cancer Vaccine Description and Business Overview
6.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
6.11.5 OncoTherapy Science Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide Cancer Vaccine Industry Chain Analysis
7.2 Peptide Cancer Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide Cancer Vaccine Production Mode & Process
7.4 Peptide Cancer Vaccine Sales and Marketing
7.4.1 Peptide Cancer Vaccine Sales Channels
7.4.2 Peptide Cancer Vaccine Distributors
7.5 Peptide Cancer Vaccine Customers
8 Peptide Cancer Vaccine Market Dynamics
8.1 Peptide Cancer Vaccine Industry Trends
8.2 Peptide Cancer Vaccine Market Drivers
8.3 Peptide Cancer Vaccine Market Challenges
8.4 Peptide Cancer Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
